CTOs on the Move

CLS Health

www.cls.health

 
CLS Health is a multi-specialty medical group with 90+ providers providing comprehensive inpatient & outpatient care in Houston, TX
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.cls.health
  • 600, North Kobayashi Road
    Webster, TX USA 77598
  • Phone: 281.724.1861

Executives

Name Title Contact Details

Similar Companies

FOCUS Pharmaceuticals

FOCUS Pharmaceuticals is a Los Angeles, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Laboratoires Vivacy

Hyaluronic Acid Experts - Aesthetics Medecine – Dermo Cosmetic - Intimate Care

Bionical Emas

Bionical Emas is the first and only CRO that combines Clinical Development, Early Access Programs and Clinical Trial Supply. We build close partnerships with our clients, so we can provide you with a unique, integrated service shaped to fit your needs.

Oyster Point Pharma

Based in Princeton, New Jersey, Oyster Point Pharma is a clinical stage pharmaceutical company leveraging neuroscience to discover, develop and commercialize novel therapies to treat diseases with high unmet needs. The company`s initial focus is to develop innovative therapeutics to treat the signs and symptoms of Dry Eye Disease (DED) by stimulating the trigeminal parasympathetic pathway to activate the glands responsible for tear film production. Oyster Point is leveraging a class of receptors called nicotinic acetylcholine receptors (nAChRs) which are located on the trigeminal nerve, accessible within the nose, to stimulate natural tear film production. The two lead product candidates, OC-01 and OC-02, are delivered via a nasal spray and are currently in Phase 2 trials for treatment of Dry Eye Disease (DED). Our leadership team brings extensive experience in developing and commercializing therapies for ophthalmic and other disease categories. Oyster Point is backed by industry leading investors, Versant Ventures and NEA and has an esteemed Board of Directors and Scientific and Medical Advisory Board.

Reata Pharmaceuticals

Reata Pharmaceuticals is the leader in discovering and developing novel, oral anti-inflammatory drugs that activate Nrf2, the primary regulator of cellular antioxidant and detoxification enzymes.